Adherium Completes Retail Entitlement Offer, Leaves Room to Place Shortfall Shares

Adherium Ltd. ( (AU:ADR) ) just unveiled an update.

Adherium Limited has completed the retail component of its 1-for-1.5 accelerated non-renounceable entitlement offer, issuing 27,734,391 new shares to raise about A$83,203 before costs, including applications under a top-up facility. Together with the earlier institutional placement and institutional entitlement offer, the overall entitlement offer raised approximately A$5.45 million, while the placement and institutional elements combined brought total proceeds to about A$6.70 million before costs.

The retail offer was not fully subscribed, leaving 244,391,217 shortfall shares that the board may place with investors within three months at no less than A$0.003 per share, potentially providing additional funding flexibility. New shares from the retail offer are scheduled for allotment on 19 March 2026 and normal trading on 20 March 2026, ranking equally with existing ordinary shares and reinforcing Adherium’s capital position to support its digital respiratory management business.

The most recent analyst rating on (AU:ADR) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Adherium Ltd. stock, see the AU:ADR Stock Forecast page.

More about Adherium Ltd.

Adherium Limited, listed on the ASX as ADR, is a provider of integrated digital health solutions focused on connected respiratory medical devices. Its FDA-cleared Hailie Smartinhaler platform and broader Hailie solution enable remote monitoring of medication usage and adherence, offering integration tools and connected sensors for clinicians, healthcare providers and patients globally.

Technical Sentiment Signal: Sell

Current Market Cap: A$13.03M

For a thorough assessment of ADR stock, go to TipRanks’ Stock Analysis page.